Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Pharming Group NV shares dropped sharply in premarket trading after the U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental New Drug Application for Joenja, citing concerns about possible underexposure in lower weight pediatric patients and problems with an analytical method used in production batch testing. The…
Bernstein analyst Gautam Chhugani argues that the recent Bitcoin sell-off may represent a rare long-term buying opportunity and possibly the final entry before Bitcoin's emergence as a sovereign asset. He points to a rapid institutional adoption via ETFs and corporate treasury purchases, notes Bitcoin's underperformance versus gold amid central ban…
Avalo Therapeutics (NASDAQ: AVTX) saw a 5.8% gain in premarket trading after Guggenheim initiated coverage with a Buy rating and a $50 price target. The firm's analyst cited the companys IL-1…
VerifyMe Inc. reported that it has satisfied Nasdaq’s minimum bid price requirement after its closing bid exceeded $1.00 for 10 consecutive business days from January 13 through January 29, 2026. The announcement came after a prior notification of non-compliance and preceded a 3.5% increase in premarket trading for the company’s shares.
Cantor Fitzgerald raised its price objective for Teradyne to $270 while keeping an Overweight rating, pointing to sustained revenue and earnings momentum tied to artificial intelligence-related businesses. The firm projects higher near-term and longer-term earnings per share, and expects company management to deliver optimistic guidance. Other anal…
France’s 2026 fiscal plan is set to pass as parliamentary no-confidence motions are expected to fail. The package seeks to narrow the deficit to 5% of GDP from an estimated 5.4% last year, after the government backed away from an earlier 4.7% target following concessions to the Socialist party. The plan combines extended levies on large firms, new …
Morgan Stanley says the release of Google’s Genie 3 world model has amplified concerns that generative world models could alter game production workflows. The bank highlights two potential trajectories for established game companies - integrating AI into existing engines or being overtaken by new technologies - and notes technical hurdles that favo…
Insmed shares have been knocked around by negative headlines on the development side, but the company already has a commercially approved DPP1 inhibitor, BRINSUPRI, with consensus peak sales potential near $5 billion. With a market cap of roughly $33.5 billion and supportive technicals, this trade idea buys the pullback into what we view as an othe…
A recent WarrenAI analysis spotlights three established companies that pair growth momentum with solid financial metrics. Cigna, First Solar and Newmont each show notable revenue expansion and analyst upside potential, while WarrenAI rates their financial health positively. These selections span healthcare, clean energy and precious metals, reflect…
Cantor Fitzgerald raised its price target on Regeneron Pharmaceuticals to $800 from $740 and kept an Overweight rating after updating near-term commercial portfolio estimates and applying modest values to several development programs. The firm highlighted obesity efforts, Dupixent lifecycle management and Factor XI research as drivers of higher val…
Scotiabank raised its 12-month price target for Verizon Communications to $50.25 from $48.00 while keeping a Sector Perform rating, citing the carrier's new churn-reduction plan and the inclusion of the Frontier acquisition in updated estimates. The bank says Verizon shares still look inexpensive, but it wants to see initial evidence that churn is …
Cantor Fitzgerald has maintained an Overweight rating on Definium Therapeutics Inc (NASDAQ:DFTX), while revising key inputs in its valuation model. The firm lowered its discount rate and adjusted penetration assumptions for two psychiatric indications, increasing its NPV estimate materially even as it trimmed EPS forecasts for 2025 and 2026. Other …
Greenland’s Prime Minister Jens-Frederik Nielsen told parliament that, despite U.S. President Donald Trump having ruled out the use of military force, Washington continues to pursue control and pathways to ownership of the Arctic island. Trump intensified calls earlier in the year for U.S. control citing national security concerns tied to Russia an…
Stephens raised its price objective on Ameris Bancorp to $87 from $79 while keeping an Equal Weight rating, citing stronger-than-expected core pre-provision net revenue (PPNR) and a firmer net interest margin (NIM). The new target implies roughly 8% upside from the stock's prevailing level and comes amid continued loan growth, elevated production, …
William Blair moved Palantir Technologies Inc. (PLTR) from Market Perform to Outperform on Monday, pointing to sustained momentum in both government and commercial channels. The upgrade, issued before Palantir’s upcoming earnings, notes strong tracker data, large partnership expansions, and enterprise adoption, even as the stock has experienced a s…
Stephens reduced its 12-month price target for Canadian National Railway (CNI) to $100 from $105 while retaining an Equal Weight rating. The move follows Q4 2025 results that beat estimates on adjusted EPS and operating ratio, but the firm cited flat revenue ton mile guidance, macroeconomic and trade-policy uncertainty, and rising expenses that lim…
Uber has confirmed it is engaged in discussions with France's social security agency URSSAF after media reports said the agency concluded tens of thousands of drivers should have been classified as employees. URSSAF is reported to be seeking substantial back payments and penalties. The matter sits alongside ongoing court scrutiny of app-based ride-…
Shares of several U.S. rare earths and critical minerals companies rose sharply after reports that the administration plans a $12 billion strategic minerals stockpile, an initiative aimed at reducing dependence on Chinese supplies. The proposal - informally referred to as Project Vault - would pair private capital with a large loan from the U.S. Ex…
Bernstein SocGen Group lowered its price target on Qualcomm to $200 from $215 while maintaining an Outperform rating. The firm cited weak sentiment toward smartphones, Apple rolloff concerns and recent memory-market dynamics as reasons for the cut, even as it highlighted Qualcomm’s strong product lineup, robust cash generation and emerging AI adjac…
Bernstein SocGen Group lowered its price target on Elevance (NYSE: ELV) to $409 from $431 while keeping an Outperform rating. The firm pointed to Elevance’s $25.50 per share guidance for 2025 and mixed fourth-quarter 2025 results - an adjusted EPS beat alongside revenue that missed expectations - as the drivers of the adjustment. Bernstein flagged …
Bernstein SocGen Group increased its price target on Air Products & Chemicals Inc. (NYSE: APD) to $315.00 from $300.00 while keeping an Outperform rating, pointing to successful execution of a 'back to basics strategy' demonstrated in the company’s first-quarter fiscal 2026 performance. The research house highlighted productivity progress, a favora…
Bernstein SocGen Group raised its price target for Regeneron Pharmaceuticals to $925 from $916 while retaining an Outperform rating, citing a solid quarter, robust cash flow and profitability metrics, and upcoming Phase 3 melanoma data for the company’s LAG3 inhibitor. Other firms have also updated targets following Regeneron’s fourth-quarter 2025 …
Saudi Arabia's stock market closed higher on Monday, with the Tadawul All Share index up 1.38% as gains in several sectors outpaced declines. Leading individual advances included Saudi Pharmaceutical Appliances, Rasan Information Technology - which reached an all-time high - and Knowledge Economic City, while select mining and industrial names lagg…
JPMorgan raised its price target on Chevron to $181 from $176 while retaining an Overweight rating, highlighting cost-savings targets tied to structural reductions and post-merger investment positioning. The bank pointed to debottlenecking at major projects and a geographically diversified upstream portfolio as potential catalysts, while recent ear…
H.C. Wainwright has reaffirmed a Buy rating and a $40.00 12-month price target on Summit Therapeutics plc (NASDAQ:SMMT) after the U.S. Food and Drug Administration accepted the company’s Biologics License Application for ivonescimab. The price target implies a roughly 176% upside from Summit’s recent trading level near its 52-week low. The FDA set …
